In a world obsessed with AI hype and consumer apps, Eigen Health is building the surgical backbone of modern oncology. They're not a startup—they're a $123.5M revenue powerhouse with 1,535 employees, and they're making prostate biopsies faster, more precise, and less invasive.

"They're not chasing AI buzzwords—they're using it to cut prostate biopsy times from 30+ minutes to 10."

The traffic data reveals an interesting pattern: 60% organic search, 20% direct. For a B2B medtech company, this suggests strong brand recognition among medical professionals. The top search term 'eigen' (14K monthly volume) shows significant brand equity, while 'eigen ai' (1.9K) indicates growing interest in their AI capabilities. The 'undefined' country data (86.3% and 13.7%) is likely a data artifact, but the split suggests international presence.

• Patented MRI/US fusion algorithm—core IP that's hard to replicate
• Dual procedure modes (transrectal & transperineal) under local or general anesthesia
• Proven clinical adoption across multiple institutions for years
• Leadership team with deep regulatory and R&D expertise (FDA compliance is critical in medtech)